We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA approval came too late for last year's flu season. But Wyeth Pharmaceuticals plans to make up for lost time with this year's launch of its nasal influenza vaccine, FluMist. It's banking on a high-tech cold chain distribution network to make it happen.
RSS
